Evidence map›Paper›PMID 25253953›Full record

ReviewWorld journal of gastroenterology2014

Mitotic crossover--an evolutionary rudiment which promotes carcinogenesis of colorectal carcinoma.

Branislav Rovcanin, Ivan Ivanovski, Olivera Djuric, Dimitrije Nikolic, Jelena Petrovic, Petar Ivanovski

Open access · bronzeAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Plant diversity · 2019
    Article
  3. FAM172A is a tumor suppressor in colorectal carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Branislav RovcaninBranislav Rovcanin, Institute for Human Genetics, Faculty of Medicine, University of Belgrade, Belgrade 11000, Serbia.
Ivan IvanovskiBranislav Rovcanin, Institute for Human Genetics, Faculty of Medicine, University of Belgrade, Belgrade 11000, Serbia.
Olivera DjuricBranislav Rovcanin, Institute for Human Genetics, Faculty of Medicine, University of Belgrade, Belgrade 11000, Serbia.
Dimitrije NikolicBranislav Rovcanin, Institute for Human Genetics, Faculty of Medicine, University of Belgrade, Belgrade 11000, Serbia.
Jelena PetrovicBranislav Rovcanin, Institute for Human Genetics, Faculty of Medicine, University of Belgrade, Belgrade 11000, Serbia.
Petar IvanovskiBranislav Rovcanin, Institute for Human Genetics, Faculty of Medicine, University of Belgrade, Belgrade 11000, Serbia.
University of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitotic crossover is a natural mechanism that is a main source of the genetic variability of primitive organisms. In complex organisms such as mammals, it represents an evolutionary rudiment which persisted as one of the numerous DNA repair mechanisms, and results in the production of homozygous allele combinations in all heterozygous genes located on the chromosome arm distal to the crossover. This event is familiar as loss of heterozygosity, which is one of the key mechanisms responsible for the development and progression of almost all cancers. We propose the hypothesis in which mitotic crossover is a principal source of the increased loss of heterozygosity that leads to the initiation and progression of colorectal carcinoma. The hypothesis could be tested by in vitro inhibition of Rad51 protein, orthotopic grafting of human colon cancer tissue into the gut of mice, and treatment with potential inhibitors. After these procedures, the frequency of mitotic crossover would be estimated. The development of selective inhibitors of mitotic crossover could stop further carcinogenesis of colorectal carcinoma, as well as many other neoplastic events. Loss of heterozygosity is an event responsible for carcinogenesis, its reduction by selective inhibitors of mitotic crossover could have a positive effect on cancer chemoprevention, as well as on growth reduction and a cessation in the progression of earlier developed tumors.

Indexed as

Evolution, MolecularGene Expression Regulation, NeoplasticLoss of HeterozygosityRecombination, GeneticAnimalsAntineoplastic AgentsCarcinomaCell Transformation, NeoplasticColorectal NeoplasmsGenetic VariationHeterozygoteHomozygoteHumansMitosisMolecular Targeted TherapyAntineoplastic AgentsCancer chemopreventionCarcinogenesisColorectal carcinomaInhibitorsLoss of heterozygosityMitotic crossing over

Identifiers

PMID25253953
PMCPMC4168086
OpenAlexW2046834898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.